Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manish Gupta

Showing results (311-320 of 343) with videos related to

Pageof 35
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|January 23, 2016
Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib StudyJesus Berdeja, Sundar Jagannath, Jeffrey Zonder, et al.
Clinical Pharmacology and Therapeutics|August 23, 2022
Semimechanistic Physiologically-Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B-Cell LymphomasTommy Li, Ida H Hiemstra, Christopher Chiu, et al.
Nature Communications|December 9, 2023
Inhibition of host PARP1 contributes to the anti-inflammatory and antitubercular activity of pyrazinamideStefanie Krug, Manish Gupta, Pankaj Kumar, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|October 19, 2017
Multimodal imaging approach to examine biodistribution kinetics of Cabotegravir (GSK1265744) long acting parenteral formulation in ratBeat M Jucker, Hasan Alsaid, Mary Rambo, et al.
Cancer Chemotherapy and Pharmacology|August 14, 2012
A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancerBrendan C Bender, Franziska Schaedeli-Stark, Reinhold Koch, et al.
Molecular Pharmaceutics|December 18, 2019
ICH M9 Guideline in Development on Biopharmaceutics Classification System-Based Biowaivers: An Industrial Perspective from the IQ ConsortiumPhilip Bransford, Jack Cook, Manish Gupta, et al.
The Lancet Regional Health. Southeast Asia|March 29, 2024
Preliminary results of hypofractionated radiotherapy in breast cancer in Chandigarh, India: single-centre, non-inferiority, open-label, randomised, phase 3 trialBudhi Singh Yadav, Divya Dahiya, Manish Gupta, et al.
Clinical Pharmacology in Drug Development|April 29, 2016
Effects of Trastuzumab Emtansine (T-DM1) on QT Interval and Safety of Pertuzumab Plus T-DM1 in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast CancerManish Gupta, Bei Wang, Timothy J Carrothers, et al.
Journal of Clinical Pharmacology|September 29, 2011
Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancerManish Gupta, Patricia M Lorusso, Bei Wang, et al.
Transplantation|February 18, 2004
West Nile virus encephalitis in organ transplant recipients: another high-risk group for meningoencephalitis and deathDebby DeSalvo, Prabir Roy-Chaudhury, Ram Peddi, et al.
Pageof 35

Showing results (311-320 of 343) with videos related to

Sort By:
Pageof 35
Clinical Lymphoma, Myeloma & Leukemia|January 23, 2016
Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib StudyJesus Berdeja, Sundar Jagannath, Jeffrey Zonder, et al.
Clinical Pharmacology and Therapeutics|August 23, 2022
Semimechanistic Physiologically-Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B-Cell LymphomasTommy Li, Ida H Hiemstra, Christopher Chiu, et al.
Nature Communications|December 9, 2023
Inhibition of host PARP1 contributes to the anti-inflammatory and antitubercular activity of pyrazinamideStefanie Krug, Manish Gupta, Pankaj Kumar, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|October 19, 2017
Multimodal imaging approach to examine biodistribution kinetics of Cabotegravir (GSK1265744) long acting parenteral formulation in ratBeat M Jucker, Hasan Alsaid, Mary Rambo, et al.
Cancer Chemotherapy and Pharmacology|August 14, 2012
A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancerBrendan C Bender, Franziska Schaedeli-Stark, Reinhold Koch, et al.
Molecular Pharmaceutics|December 18, 2019
ICH M9 Guideline in Development on Biopharmaceutics Classification System-Based Biowaivers: An Industrial Perspective from the IQ ConsortiumPhilip Bransford, Jack Cook, Manish Gupta, et al.
The Lancet Regional Health. Southeast Asia|March 29, 2024
Preliminary results of hypofractionated radiotherapy in breast cancer in Chandigarh, India: single-centre, non-inferiority, open-label, randomised, phase 3 trialBudhi Singh Yadav, Divya Dahiya, Manish Gupta, et al.
Clinical Pharmacology in Drug Development|April 29, 2016
Effects of Trastuzumab Emtansine (T-DM1) on QT Interval and Safety of Pertuzumab Plus T-DM1 in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast CancerManish Gupta, Bei Wang, Timothy J Carrothers, et al.
Journal of Clinical Pharmacology|September 29, 2011
Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancerManish Gupta, Patricia M Lorusso, Bei Wang, et al.
Transplantation|February 18, 2004
West Nile virus encephalitis in organ transplant recipients: another high-risk group for meningoencephalitis and deathDebby DeSalvo, Prabir Roy-Chaudhury, Ram Peddi, et al.
Pageof 35